| 施骅.血管加压素V2受体拮抗剂托伐普坦治疗肝硬化并低钠血症患者临床疗效及安全性评价[J].浙江中西医结合杂志,2017,27(1): |
| 血管加压素V2受体拮抗剂托伐普坦治疗肝硬化并低钠血症患者临床疗效及安全性评价 |
| Vasopressin V2 receptor antagonist tolvaptan treatment of liver cirrhosis and hyponatremia clinical efficacy and safety evaluation |
| 投稿时间：2016-06-04 修订日期：2016-11-08 |
| DOI： |
| 中文关键词: 托伐普坦 肝硬化 低钠血症 疗效 安全性 |
| 英文关键词:tolvaptan cirrhosis hyponatremia efficacy safety |
| 基金项目: |
|
| 摘要点击次数: 931 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的：探讨血管加压素V2受体拮抗剂托伐普坦治疗肝硬化并低钠血症患者临床疗效及安全性评价。方法：选自我院于2014年1月~2015年12月肝硬化并低钠血症患者72例,按照随机数字表法随机分为观察组36例与对照组36例。对照组采用常规治疗,观察组在对照组基础上结合托伐普坦治疗。两组疗程均为7d。比较两组治疗疗效,治疗前后血钠、尿钠、血尿酸、肾功能指标水平变化及药物不良反应情况。结果：观察组总有效率(88.89%)高于对照组(66.67%)(P<0.05)；两组血钠、尿钠、血尿酸水平治疗后增加(P<0.05)；观察组血钠、尿钠、血尿酸水平治疗后高于对照组(P<0.05)；两组血清BUN和Cr水平治疗前比较无统计学差异(P>0.05)；两组血清BUN和Cr水平治疗后前后无变化(P>0.05)；两组均未见严重不良反应。结论：血管加压素V2受体拮抗剂托伐普坦治疗肝硬化并低钠血症患者临床疗效显著,且安全性良好,值得研究。 |
| 英文摘要: |
| Objective: To evaluate vasopressin V2 receptor antagonist tolvaptan treatment of liver cirrhosis and hyponatremia clinical efficacy and safety evaluation. Methods: selected from our hospital in January 2014 ~ December 2015 cirrhosis and hyponatremia hyperlipidemia 72 patients were randomly divided into observation group 36 cases and control group 36 patients. Control group with conventional treatment, observation group incorporated in the control group on the basis of tolvaptan treatment. The treatment lasted 7d. Comparison of the efficacy of treatment in both groups, before and after treatment serum sodium and urine sodium, uric acid, renal function levels and adverse drug reactions. Results: The total efficiency observation group (88.89%) was higher control group (66.67%) (P<0.05); two groups of serum sodium and urine sodium, uric acid levels after treatment increased (P<0.05); the observation group sodium, urinary sodium, uric acid levels after treatment was higher (P<0.05); two groups serum BUN and Cr levels before treatment no significant difference (P>0.05); serum BUN and Cr groups before and after treatment did not change the level of (P>0.05); two groups were no serious adverse reactions. Conclusion: vasopressin V2 receptor antagonist tolvaptan treatment of liver cirrhosis and hyponatremia significant clinical efficacy in patients with hyperlipidemia, and the security is good, is worth studying. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
